menu
    • menu

    Company profile for Gelesis

    NEW Drugs in Dev: 3
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Gelesis is a biotechnology company developing a novel category of potential therapies for GI-related chronic diseases including obesity, NAFLD/NASH, IBD and type 2 diabetes by targeting the natural processes of the GI pathway. Utilizing our novel hydrogel platform technology and the emerging science of mechanobiology, we are developing innovative approaches to target the cause of those epidemics rather than just improving thei...
    Gelesis is a biotechnology company developing a novel category of potential therapies for GI-related chronic diseases including obesity, NAFLD/NASH, IBD and type 2 diabetes by targeting the natural processes of the GI pathway. Utilizing our novel hydrogel platform technology and the emerging science of mechanobiology, we are developing innovative approaches to target the cause of those epidemics rather than just improving their symptoms. Our first-in-class products are designed to trigger multiple mechanisms throughout the GI system related to satiety, glycemic control, gut permeability and inflammation.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GelesisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    501 Boylston St. Suite 6102. Boston, MA 02116
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gelesis.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/gelesis-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gelesis’ Oral Treatment for Weight Management Showed Real-World Effectiveness
    Gelesis’ Oral Treatment for Weight Management Showed Real-World Effectiveness

    26 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230626231353/en

    BUSINESSWIRE
    26 Jun 2023
    Share Share
    Gelesis Reports Fourth Quarter and Full Year 2022 Results
    Gelesis Reports Fourth Quarter and Full Year 2022 Results

    28 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230328005292/en

    BUSINESSWIRE
    28 Mar 2023
    Share Share
    Gelesis to Participate in the 25th Annual ICR Conference
    Gelesis to Participate in the 25th Annual ICR Conference

    05 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230105005182/en

    BUSINESSWIRE
    05 Jan 2023
    Share Share
    Gelesis Receives Notice of NYSE Market Capitalization Rule Non-Compliance
    Gelesis Receives Notice of NYSE Market Capitalization Rule Non-Compliance

    18 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221118005569/en

    BUSINESSWIRE
    18 Nov 2022
    Share Share
    Gelesis Reports Third Quarter 2022 Results
    Gelesis Reports Third Quarter 2022 Results

    14 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221114005413/en

    BUSINESSWIRE
    14 Nov 2022
    Share Share
    Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance
    Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance

    04 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221104005601/en

    BUSINESSWIRE
    04 Nov 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search